Mirum Pharmaceuticals, Inc. (MIRM) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended June 30, 2025. Mirum Pharmaceuticals is a biopharmaceutical company focused on rare diseases, commercializing three approved medicines: LIVMARLI (maralixibat), Cholbam (cholic acid), and Ctexli (chenodiol, formerly Chenodal). The company operates as a single segment and is classified as a large accelerated filer.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 | Q2 2024 | 6 Months 2025 | 6 Months 2024 |
|---|---|---|---|---|
| Total Revenue | $127,785 | $77,875 | $239,370 | $147,097 |
| Net Loss | $(5,861) | $(24,638) | $(20,538) | $(49,917) |
| Loss Per Share (Basic/Diluted) | $(0.12) | $(0.52) | $(0.42) | $(1.06) |
| Operating Cash Flow (6mo) | $10,079 | $11,409 | $10,079 | $11,409 |
| Cash & Investments (Total) | $321,700 | N/A | $321,700 | N/A |
| Convertible Notes (Principal) | $316,241 | N/A | $316,241 | N/A |
Note: Cash and investments figure represents unrestricted cash, cash equivalents, and investments as of June 30, 2025.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased by 64% year-over-year for the quarter ($127.8M vs. $77.9M) and 63% for the six-month period ($239.4M vs. $147.1M). This growth was driven by continued commercialization of Livmarli and Bile Acid Medicines, including an $11.0 million adjustment in Q2 2025 due to changes in estimated variable consideration for distributor inventory.
- Expense Increases: Operating expenses rose significantly. Research and Development (R&D) expenses increased by 41% in Q2 ($46.1M vs. $32.7M) due to increased clinical trial costs for volixibat and MRM-3379. Selling, General, and Administrative (SG&A) expenses increased by 29% in Q2 ($63.3M vs. $49.2M) primarily due to higher personnel and stock-based compensation costs.
- Improved Profitability: Net loss narrowed substantially to $5.9M in Q2 2025 compared to $24.6M in Q2 2024, reflecting revenue growth outpacing expense increases.
Guidance, Outlook, and Risks
- Liquidity: Management believes existing unrestricted cash and investments of $321.7 million are sufficient to fund operations for at least 12 months from the filing date.
- Convertible Notes: The company's 4.00% Convertible Senior Notes due 2029 are currently convertible at the option of holders during the third quarter of 2025 (July 1 – September 30, 2025) because the stock price exceeded 130% of the conversion price for the requisite period. The company may settle conversions in cash, stock, or a combination.
- Development Pipeline: The company expects to initiate a Phase 2 clinical trial for MRM-3379 (Fragile-X Syndrome) in Q4 2025. Enrollment for the VISTAS Phase 2b trial (volixibat in PSC) is expected to complete in Q3 2025.
- Regulatory & Tax Risks: The company is assessing the impact of the "One Big Beautiful Bill Act" signed into law on July 4, 2025, which includes changes to U.S. federal tax law. Additionally, the company faces risks related to patent protection for certain approved medicines and reliance on third-party manufacturers.
Investor Verification Checklist
- Convertible Note Conversion: Verify the extent of any conversions of the $316.2M convertible notes during Q3 2025 and the settlement method (cash vs. stock) to assess potential dilution or cash outflow.
- Revenue Recognition Adjustments: Monitor future quarters for volatility in revenue due to the company's reliance on estimated variable consideration from distributors and partners (e.g., Takeda).
- Cash Burn vs. Revenue: Track the trajectory of operating cash flow to ensure it remains positive as R&D and SG&A expenses continue to rise with clinical trial expansions.
- Regulatory Milestones: Confirm the timeline for the MRM-3379 Phase 2 initiation and the topline data release for the volixibat VISTAS trial (expected Q2 2026).
- Intellectual Property: Review the status of patent protection for Livmarli and the Bile Acid Medicines, noting the lack of composition-of-matter patents for certain products.